Month: June 2020

Apellis Pharmaceuticals to Present at the BMO 2020 Prescriptions for Success Healthcare Conference

Written by Customer Service on June 16, 2020. Posted in Public Companies.

WALTHAM, Mass., June 16, 2020 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) a global biopharmaceutical company pioneering targeted C3 therapies, today announced that the company will present at the BMO 2020 Prescriptions for Success Healthcare Conference on Tuesday, June 23, 2020 at 11:30 a.m. ET. The conference will be held in a virtual meeting format.Cedric Francois, M.D., Ph.D., co-founder and chief executive officer of Apellis, will participate in a fireside chat. The event will be available via live webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s website at https://investors.apellis.com/events-and-presentations. A replay of the webcast will be available for 90 days following the event.About ApellisApellis Pharmaceuticals, Inc. is a global biopharmaceutical...

TG Therapeutics to Present at the Raymond James 2020 Human Health Innovation Conference

Written by Customer Service on June 16, 2020. Posted in Public Companies.

NEW YORK, June 16, 2020 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will present at the Raymond James 2020 Human Health Innovation Conference, being held virtually. The presentation is scheduled to take place on Thursday, June 18, 2020, at 3:40 PM ET.A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company’s website at http://ir.tgtherapeutics.com/events.ABOUT TG THERAPEUTICS, INC. TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing multiple therapies targeting hematological...

Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX®2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome Clinical Trial

Written by Customer Service on June 16, 2020. Posted in Public Companies.

NEW YORK, June 16, 2020 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that it has surpassed by 50% the company’s original enrollment target for the ANAVEX®2-73 (blarcamesine) U.S. Phase 2 study in Rett syndrome. The Company expects to announce topline results from this study in 2H 2020.ANAVEX®2-73 (blarcamesine) is an orally available, small-molecule activator of the sigma-1 receptor which, data suggest, is pivotal to restoring neural cell homeostasis and promoting neuroplasticity.1The multi-center, double-blind...

9F Inc. to Report Fourth Quarter and Full Year 2019 Unaudited Financial Results on June 17, 2020

Written by Customer Service on June 16, 2020. Posted in Public Companies.

BEIJING, June 16, 2020 (GLOBE NEWSWIRE) — 9F Inc. (“9F” or “the Company”) (NASDAQ: JFU), a leading digital financial account platform integrating and personalizing financial services in China, today announced that it will release its unaudited financial results for the fourth quarter and full year ended December 31, 2019, before the open of U.S. markets on Wednesday, June 17, 2020.About 9F Inc.9F Inc. is a leading digital financial account platform integrating and personalizing financial services in China with the footprint expanding overseas. The Company provides a comprehensive range of financial products and services across loan products, online wealth management products, and payment facilitation, all integrated under a single digital financial account.For more information, please visit http://ir.9fgroup.com/For investor and media...

FLYHT to hold virtual 2020 AGM

Written by Customer Service on June 16, 2020. Posted in Public Companies.

CALGARY, Alberta, June 16, 2020 (GLOBE NEWSWIRE) — FLYHT Aerospace Solutions Ltd. (TSX-V: FLY) (OTCQX: FLYLF) (the “Company” or “FLYHT”) will hold its 2020 Annual and Special Meeting on June 23, 2020 at 9:00 am MT (11:00am ET).To protect the health and safety of the public and our team members in light of the COVID-19 situation, FLYHT’s 2020 Annual and Special Meeting will be held virtually only, accessible online at:https://us02web.zoom.us/s/86195986522?pwd=RzErcHJhaFEzUDFYbVQra2hPNGxqQT09or by phone:Canada: +1 647 558 0588 or +1 778 907 2071 or +1 438 809 7799 or +1 587 328 1099 or +1 647 374 4685US: +1 312 626 6799 or +1 346 248 7799 or +1 646 558 8656 or +1 669 900 9128 or +1 253 215 8782 or +1 301 715 8592Webinar ID: 861 9598 6522Password: 914819International numbers available: https://us02web.zoom.us/u/kdhH8O9Hy7Shareholders...

Commercial Vehicle Rental and Leasing Market to Reach USD 116.72 Billion by 2027; Improved In-vehicle User-Experience in Commerical Cars to Augment Growth, states Fortune Business Insights

Written by Customer Service on June 16, 2020. Posted in Mergers And Acquisitions.

Pune, June 16, 2020 (GLOBE NEWSWIRE) — The global commercial vehicle rental and leasing market size is expected to reach USD 116.72 billion by 2027, exhibiting a CAGR of 8.0% during the forecast period. The growing inclination on truck leases or rentals to dismiss the financial responsibility of servicing, maintenance, and vehicle replacement will facilitate the healthy growth of the market during the forecast period, states Fortune Business Insights in a report, titled “Commercial Vehicle Rental and Leasing Market Size, Share & Covid-19 Impact Analysis, By Rent Type (Business and Personal Use), By Vehicle Type (Car, Light Commercial Vehicle, and Medium/Heavy Commercial Vehicle), and Regional Forecasts, 2020-2027” the market size stood at USD 86.33 billion in 2019. The adoption of various marketing strategies by rental companies...

Construction starts for floating solar plant in Albania

Written by Customer Service on June 16, 2020. Posted in Public Companies.

Statkraft and its supplier Ocean Sun is ready to start the construction of the planned 2 MWp floating solar pilot project in Albania. The pilot has an estimated total investment of EUR 2 million and will be placed at the Banja reservoir, where Statkraft is operating its 72 MW Banja hydropower plant.“Now that all regulatory approvals are in place, we have issued a notice to proceed to Ocean Sun for implementing the first phase of the project. We look forward to start construction by the end of June”, says Head Advisor IP Strategy and Asset Management in Statkraft, Tom Kristian Larsen.In this first phase, Ocean Sun will deliver a complete floating 0.5 MWp DC system based on their innovative design for floating solar technology. The floating power plant will be constructed in collaboration between Ocean Sun and Statkraft, and is expected...

Starter bygging av flytende solkraftverk i Albania

Written by Customer Service on June 16, 2020. Posted in Public Companies.

Statkraft og den norske leverandøren Ocean Sun er klare til å starte byggingen av det planlagte pilotanlegget for flytende solkraft i Albania. Piloten har en investeringsramme på 2 millioner euro og skal bygges i reservoaret til Statkrafts eksisterende vannkraftverk i Banja.– Nå som alle godkjenningene er på plass, har vi formelt bedt Ocean Sun om å starte fase 1 i byggeprosjektet. Vi ser frem til å komme i gang med byggingen i løpet av juni, sier seniorrådgiver Tom Kristian Larsen i Statkraft.I fase 1 vil Ocean Sun levere et komplett flytende solkraftverk på 0,5 MWp basert på deres innovative design for flytende solkraft. Anlegget bygges i tett samarbeid med Statkraft og er forventet ferdig i 4. kvartal 2020.Når den første enheten leverer i tråd med krav og spesifikasjoner vil Statkraft starte fase 2, som omfatter ytterligere tre...

National Storm Recovery, Inc. (NSRI) Reports Over $1.7 Million in Gross Profit & Over $34.7 Million in Total Assets Within its 1st Quarter Ending March 31st, 2020

Written by Customer Service on June 16, 2020. Posted in Earnings Releases And Operating Results.

ORLANDO, Fla., June 16, 2020 (GLOBE NEWSWIRE) — National Storm Recovery Inc. (OTC: NSRI) (“NSRI” or the “Company”), a leading provider of environmentally beneficial solutions for tree and storm waste disposal, today announces first quarter financial results (for the 3 month period ending March 31, 2020 as already reported on otcmarkets.com).Within the Company’s first quarter 2020, utilizing only approximately 2 months of post-acquisition revenue of Mulch Manufacturing, the Company recorded revenues of $6,255,262, $1,728,506 of gross profit, and $34,711,993 in total assets, including $4,303,668 of cash.Tony Raynor, NSRI’s CEO, comments: “This year’s first quarter has been extraordinary! We have made major upgrades at our key production facility to increase our production. We are prepared to meet the challenges and have planned accordingly...

Mereo BioPharma Announces Financial Results for the Year Ended December 31, 2019

Written by Customer Service on June 16, 2020. Posted in Earnings Releases And Operating Results.

LONDON and REDWOOD CITY, Calif., June 16, 2020 (GLOBE NEWSWIRE) — Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced financial results for the 12 months ended December 31, 2019.“We are very pleased with the substantial operational progress we have made throughout 2019 and particularly, over the past several months,” said Dr. Denise Scots-Knight, Chief Executive Officer of Mereo. “We announced earlier this month that we have taken the strategic decision to focus on advancing etigilimab, (an “Anti-TIGIT”) for the treatment of solid tumors, alongside our rare disease portfolio including setrusumab for osteogenesis imperfecta, which we plan to partner prior to the initiation of a pivotal Phase 3 study, and alvelestat...

Month: June 2020

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals